• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 480983 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419279905 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419279905 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Keryx Biopharmaceuticals Crosses Below its 10-day MA (KERX)

Published on Wed, 04/17/2013 - 11:32
By Peter Chu

Today, shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have fallen below their 10-day MA of $7.75 on a volume of 677K shares. This may provide swing traders with an opportunity for a short position, as such a crossover often suggests lower prices in the near term.

In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $1.28 and a high of $9.98 and are now at $7.61, which is 495% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.3% while the 200-day MA has risen 2.5%.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.

Keryx Biopharmaceuticals has overhead space with shares priced $7.61, or 40.8% below the average consensus analyst price target of $12.86. The stock should find initial support at its 50-day moving average (MA) of $7.11 and further support at its 200-day MA of $3.76.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Recent 52-Week High Exceeded in Shares o...

Quest Diagnostics (NYSE:DGX) traded at a new 52-week high today of $67.13. So far toda ...

Shares of EI Du Pont de Nemours Rise to ...

Shares of EI Du Pont de Nemours (NYSE:DD) traded at a new 52-week high today of $73.85. ...

DCT Industrial Trust: 52-Week High Recen...

DCT Industrial Trust (NYSE:DCT) traded today at a new 52-week high of $35.26. This new ...

Dominion Resources: The Winning Streak C...

Dominion Resources (NYSE:D) traded at a new 52-week high today of $76.97. This new hig ...

Shares of Cypress Semiconductor Rise to ...

Cypress Semiconductor (NYSE:CY) traded today at a new 52-week high of $14.43. This new ...

Corrections of America: The Winning Stre...

Corrections of America (NYSE:CXW) traded today at a new 52-week high of $37.62. So far ...

CVS Caremark: 52-Week High Recently Ecli...

Shares of CVS Caremark (NYSE:CVS) traded today at $97.00, breaking its 52-week high. T ...

Shares of CubeSmart Have Risen Above Pre...

Shares of CubeSmart (NYSE:CUBE) traded at a new 52-week high today of $22.80. This new ...